Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310201 | 0.87 | CACNA1G (0.44) | SMN1; SMN2POLBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL6319241 | 0.84 | HPGD (0.40) | POLBS1PR1S1PR5 | |
| SCHEMBL6311319 | 0.73 | HTR2C (0.35) | MAOBMAPT | |
| SCHEMBL6316979 | 0.71 | HTR2C (0.43) | SMN1; SMN2POLBCACNA1GCACNA1HCACNA1I | |
| SCHEMBL5746496 | 0.67 | GRIN2B (0.44) | SCN4APOLBS1PR1S1PR5 | |
| SCHEMBL3283306 | 0.66 | CCR5 (0.41) | SCN4A | |
| SCHEMBL25366111 | 0.65 | HTR2C (0.41) | MAOB | |
| SCHEMBL25363491 | 0.65 | HTR2C (0.41) | MAOB | |
| SCHEMBL4692053 | 0.65 | ALDH1A1 (0.39) | SMN1; SMN2POLBS1PR1S1PR5 | |
| SCHEMBL5746618 | 0.65 | HSD11B1 (0.46) | SCN4APOLBS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | SCN4A 458/4885SMN1; SMN2 2634/4885POLB 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.